La vendita allo scoperto per Altamira Therapeutics dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Altamira Therapeutics. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Altamira Therapeutics (NASDAQ:CYTO) Azioni, Report sulle vendite allo scoperto

Altamira Therapeutics

Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens. The company's OligoPhore / SemaPhore platform is a versatile system that allows the complexation of therapeutic RNAs with a proprietary peptide to form a nanoparticle formulation. This formulation allows to deliver of therapeutic RNA by systemic administration to tissues affected by leaky vasculature, a hallmark of solid tumors and certain inflammatory conditions.

Altamira Therapeutics Ltd. - Common Shares

Altamira Therapeutics Ltd

CytoDyn Inc

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics Ltd

CytoSorbents Corp

Cytokinetics, Incorporated - Common Stock

Cytokinetics Inc

CytomX Therapeutics Inc

CYTOPHAGE TECHS INC by CYTOPHAGE TECHNOLOGIES INC

Cytophage Technologies Ltd

BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. The company reported quarterly sales of $41.505 million which missed the analyst consensus estimate of $46.030 million by 9.83 percent. This is a 22.12 percent increase over sales of $33.988 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

BBAI

BigBear.ai Hldgs Q3 2024 GAAP EPS $(0.05) Beats $(0.07) Estimate, Sales $41.505M Miss $46.030M Estimate

Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.65 by 27.69 percent. The company reported quarterly sales of $625.71 million which beat the analyst consensus estimate of $603.93 million by 3.61 percent. This is a 63.10 percent increase over sales of $383.64 million the same period last year.

GMED

Globus Medical Q3 2024 Adj EPS $0.83 Beats $0.65 Estimate, Sales $625.71M Beat $603.93M Estimate

WIIM

B&G Foods shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 net sales guidance below estimates.

Acadia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction.
Acadia was granted the PRV in March 2023 following approval by the U.S. Food and Drug Administration (FDA) of DAYBUE&#x2122; (trofinetide) for the treatment of Rett syndrome. DAYBUE was initially licensed by Acadia from Neuren Pharmaceuticals Limited in August 2018. Pursuant to the license agreement, Acadia is required to pay Neuren one-third of the net proceeds.
Acadia plans to invest proceeds from the sale of the PRV to support its commercial operations, R&amp;D programs in central nervous system and rare disease, and future business development.
The transaction is subject to customary closing conditions, including expiration of applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Jefferies LLC acted as financial advisor to Acadia on this transaction.

Asset Sales

ACAD

Acadia Pharmaceuticals Enters Into An Agreement To Sell Its Rare Pediatric Disease Priority Review Voucher For $150M

Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) reported quarterly earnings of $0.14 per share. The company reported quarterly sales of $37.640 million which missed the analyst consensus estimate of $42.000 million by 10.38 percent. This is a 649.35 percent increase over sales of $5.023 million the same period last year.

GIFI

Gulf Island Fabrication Q3 2024 GAAP EPS $0.14, Sales $37.640M Miss $42.000M Estimate

Ternium Q3 2024 EPADS $0.16, Sales $4.480B Beat $4.446B Estimate

New preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM) and enhanced potency to better target solid tumors will be presented at SITC
Additional profiling of patient responses in P-BCMA-ALLO1 Phase 1 Arm C and preclinical P-CD19CD20-ALLO1 to be presented at ASH
SAN DIEGO, Nov. 5, 2024 /PRNewswire/ --&nbsp;Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced new preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM), along with platform enhancements aimed at enhancing potency and improving targeting of solid tumors, will be presented at the Society for Immunotherapy of Cancer (SITC) 39th&nbsp;Annual Meeting in Houston, November 6-10.

Biotech

General

PSTX

Poseida Therapeutics To Present Clinical And Preclinical Data On Investigational Allogeneic CAR-T Cell Therapies At SITC 2024 And ASH 2024

Guidance

QLYS

Qualys Expects Q4 Adj EPS Of $1.28 - $1.38 (Est $1.28), Revenues Of $154.5M - $157.5M (Est $154.059M)

MGNX

MacroGenics shares are trading higher after the company reported better-than-expected Q3 financial results.

International Flavors & Fragrances Sees FY24 Sales $11.3B-$11.4B Vs $11.288B Est.

–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Real World Study Compared Over 150,000 Adult &amp; Pediatric Patients – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor Associated with Fewer Adverse Drug Reactions – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor also Improved Healthcare Utilization –
NASHVILLE, Tenn., Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) today announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its Caldolor (ibuprofen) injection over ketorolac in both adult and pediatric populations. The study, published in Frontiers of Pain Research, provides compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse drug reactions (ADRs) and improved healthcare utilizations when compared to ketorolac.
This extensive, retrospective, payer database analysis evaluated the records of over 17 million patients who had received either ketorolac or Caldolor. Ultimately, 31,046 Caldolor and 124,184 ketorolac adult patients were selected and compared for ADRs and subsequent healthcare resource utilization, which includes inpatient, outpatient and emergency department visits as well as all procedures and prescriptions during the follow up time of 29 days. An additional 5,579 pediatric patients were identified in each arm and compared in a separate claims analysis.
Key findings reveal that, in adults, Caldolor was associated with a 45% reduction in renal dysfunction (p&lt;0.001) and a 78% decrease in hematuria rates (p&lt;0.001) when compared to ketorolac. Notably, patients also experienced fewer gastrointestinal complications as well as reduced headaches, nausea and abdominal pain. Among pediatric patients, the results showed Caldolor was associated with a 51-65% lower rate of ADRs, including headache and nausea, with 95% confidence intervals supporting clinical significance.
Caldolor also demonstrated a positive impact on healthcare resource utilization (HCRU) when compared to ketorolac, with decreased emergency room and outpatient visits, as well as a shortened hospital length of stay for both adults and children.

CPIX

Cumberland Pharmaceuticals Announces The Publication Of New Real-World Outcomes Research Demonstrating The Safety And Healthcare Resource Advantages Of Its Caldolor (Ibuprofen) Injection Over Ketorolac In Both Adult And Pediatric Populations

AVNW

Aviat Networks shares are trading lower after the company reported worse-than-expected Q1 financial results and lowered its FY25 sales guidance.

Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) affirms FY2024 Adj EPS guidance from $1.37-1.57 to $1.37-1.57 vs $1.46 analyst estimate. Affirms FY2024 sales outlook from $425.00 million-435.00 million to $425.00 million-435.00 million vs $430.33 million estimate.

FORR

Forrester Res Affirms FY2024 Adj EPS Guidance from $1.37-1.57 to $1.37-1.57 vs $1.46 Est; Affirms FY2024 Sales Guidance from $425.00M-435.00M to $425.00M-435.00M vs $430.33M Est.

Sixth Street Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLX#NYSE">TSLX</a>) reported quarterly earnings of $0.57 per share which met the analyst consensus estimate. This is a 5 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $119.223 million which beat the analyst consensus estimate of $118.508 million by 0.60 percent. This is a 4.18 percent increase over sales of $114.435 million the same period last year.

TSLX

Sixth Street Specialty Q3 2024 Adj. EPS $0.57, Inline, Sales $119.223M Beat $118.508M Estimate

Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) reported quarterly earnings of $0.84 per share. This is a 14.29 percent decrease over earnings of $0.98 per share from the same period last year. The company reported $74.33 million in sales this quarter. This is a 11.67 percent decrease over sales of $84.15 million the same period last year.

WEYS

Weyco Group Q3 EPS $0.84 Down From $0.98 YoY, Sales $74.33M Down From $84.15M YoY

Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) reported quarterly earnings of $1.04 per share which missed the analyst consensus estimate of $1.08 by 3.7 percent. The company reported quarterly sales of $2.92 billion which beat the analyst consensus estimate of $2.83 billion by 3.29 percent. This is a 3.72 percent increase over sales of $2.82 billion the same period last year.

Intl Flavors & Fragrances Q3 2024 Adj EPS $1.04 Misses $1.08 Estimate, Sales $2.92B Beat $2.83B Estimate

Weyco Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) (the "Company") announced that today its Board of Directors declared a special one-time cash dividend of $2.00 per share, for a total of approximately $19.0 million based on the number of shares currently outstanding. The dividend will be paid on January 2, 2025, to shareholders of record at the close of business on November 18, 2024.

Dividends

Weyco Group Declares Special Cash Dividend Of $2.00 Per Share, For A Total Of ~$19M Based On The Number Of Shares Currently Outstanding

Offerings

PLBY

Playboy Announced The Closing Of Its Sale Of 14.9M Newly Issued Shares In A Private Placement At A Price Of $1.50 Per Share For A Total Purchase Price Of $22.35M

SMCI

Super Micro Computer shares are trading lower after the company lowered its financial outlook.

MCHP

Microchip Sees Q3 2024 Adj. EPS $0.29-$0.32

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news today!



Moving stocks this morning are a merger update, earnings reports, a fraud investigation and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) stock is rocketing more than 113% alongside heavy pre-market trading.</li>



<li>SciSparc (NASDAQ:<a href="https://investorplace.com/stock-quotes/sprc-stock-quote/">SPRC</a>) shares are soaring over 89% <a href="https://www.nasdaq.com/press-release/scisparc-updates-regarding-status-automax-merger-2024-08-14">on a merger update</a>.</li>



<li>Altamira Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyto-stock-quote/">CYTO</a>) stock is surging more than 43% with strong early morning trading.</li>



<li>Airship AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/aisp-stock-quote/">AISP</a>) shares are gaining over 26% after releasing its <a href="https://www.nasdaq.com/press-release/airship-ai-reports-second-quarter-2024-financial-results-2024-08-14">Q2 earnings report</a>.</li>



<li>Accuray (NASDAQ:<a href="https://investorplace.com/stock-quotes/aray-stock-quote/">ARAY</a>) stock is increasing more than 23% with its <a href="https://www.nasdaq.com/press-release/accuray-reports-fourth-quarter-and-fiscal-2024-financial-results-2024-08-14">fiscal Q4 earnings</a>.</li>



<li>Lumentum (NASDAQ:<a href="https://investorplace.com/stock-quotes/lite-stock-quote/">LITE</a>) shares are rising over 16% after <a href="https://finance.yahoo.com/news/lumentum-lite-q4-earnings-revenues-211505675.html">beating fiscal Q4 estimates</a>.</li>



<li>Sirius XM (NASDAQ:<a href="https://investorplace.com/stock-quotes/siri-stock-quote/">SIRI</a>) stock is climbing more than 14% without any clear news this morning.</li>



<li>Ulta Beauty (NASDAQ:<a href="https://investorplace.com/stock-quotes/ulta-stock-quote/">ULTA</a>) shares are heading over 14% higher as <a href="https://www.investopedia.com/warren-buffett-berkshire-hathaway-q2-2024-13f-stock-investments-ulta-beauty-heico-apple-8695592">Warren Buffettt buys the stock</a>.</li>



<li>Onconetix (NASDAQ:<a href="https://investorplace.com/stock-quotes/onco-stock-quote/">ONCO</a>) stock is jumping more than 13% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318523992&amp;type=PDF&amp;symbol=ONCO&amp;cdn=bf9be7db95f431594e22ef6ab2dce88a&amp;companyName=Onconetix+Inc.&amp;formType=NT+10-Q&amp;formDescription=Notification+of+inability+to+timely+file+Form+10-Q+or+10-QSB&amp;dateFiled=2024-08-14">alongside preliminary earnings</a>.</li>



<li>Origin Mat (NASDAQ:<a href="https://investorplace.com/stock-quotes/orgn-stock-quote/">ORGN</a>) shares are up over 11% with its <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318523578&amp;type=PDF&amp;symbol=ORGN&amp;cdn=ec1db2e58a1f10bf57b84b9fe1093283&amp;companyName=Origin+Materials+Inc.&amp;formType=10-Q&amp;formDescription=General+form+for+quarterly+reports+under+Section+13+or+15%28d%29&amp;dateFiled=2024-08-14">latest earnings report</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Turnstone Biologics (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsbx-stock-quote/">TSBX</a>) stock is plummeting more than 38% after releasing its <a href="https://www.nasdaq.com/press-release/turnstone-biologics-corp-reports-second-quarter-2024-financial-results-and-provides">Q2 earnings report</a>.</li>



<li>Titan Machinery (NASDAQ:<a href="https://investorplace.com/stock-quotes/titn-stock-quote/">TITN</a>) shares are diving over 27% with its <a href="https://www.nasdaq.com/press-release/titan-machinery-inc-announces-preliminary-results-fiscal-second-quarter-ended-july-31">preliminary earnings report</a>.</li>



<li>Jianzhi Education Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/jz-stock-quote/">JZ</a>) stock is tumbling more than 22% on Thursday morning.</li>



<li>Spire Global (NYSE:<a href="https://investorplace.com/stock-quotes/spir-stock-quote/">SPIR</a>) shares are taking an over 21% beating <a href="https://www.globenewswire.com/news-release/2024/08/14/2930592/0/en/Spire-Global-Inc-Investors-Company-Investigated-by-the-Portnoy-Law-Firm.html">on a fraud investigation</a>.</li>



<li>Hempacco (NASDAQ:<a href="https://investorplace.com/stock-quotes/hpco-stock-quote/">HPCO</a>) stock is sliding 20% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318524553&amp;type=PDF&amp;symbol=HPCO&amp;cdn=041c8fee90a6a2a4aab897fbf610d8a1&amp;companyName=Hempacco+Co.+Inc.&amp;formType=NT+10-Q&amp;formDescription=Notification+of+inability+to+timely+file+Form+10-Q+or+10-QSB&amp;dateFiled=2024-08-14">delaying its earnings report</a>.</li>



<li>Vicinity Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/vev-stock-quote/">VEV</a>) shares are dropping more than 18% after applying for a <a href="https://www.nasdaq.com/press-release/vicinity-motor-corp-applies-management-cease-trade-order-2024-08-14">cease trade order</a>.</li>



<li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) stock is decreasing over 17% on <a href="https://finance.yahoo.com/news/faraday-future-announces-reverse-stock-100000210.html">reverse split plans</a>.</li>



<li>Dragonfly Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/dfli-stock-quote/">DFLI</a>) shares are falling more than 16% on <a href="https://finance.yahoo.com/news/dragonfly-energy-holdings-corp-dfli-213503529.html">lackluster Q2 results</a>.</li>



<li>Safe &amp; Green Development (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgd-stock-quote/">SGD</a>) stock is slipping over 14% after <a href="https://www.stocktitan.net/news/SGD/safe-and-green-development-corporation-secures-strategic-investment-0zc93fwswgs0.html">rallying yesterday on investment news</a>.</li>



<li>Avalon Globocare (NASDAQ:<a href="https://investorplace.com/stock-quotes/albt-stock-quote/">ALBT</a>) shares close out our pre-market stock movers down more than 14% <a href="https://investorplace.com/2024/08/why-is-avalon-globocare-albt-stock-up-173-today/">following a rally yesterday</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-aug-15th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Altamira Therapeutics files mixed shelf offering

Altamira Therapeutics extends distribution agreement with Pharma Nordic

Altamira Therapeutics prices up to $12M public offering

Altamira Therapeutics (CYTO) has released an update. Altamira Therapeutics Ltd. has issued a pre-funded common share purchase warrant, enabling hol...

Altamira Issues Pre-Funded Share Purchase Warrant

Altamira Therapeutics reports 1H results

Altamira Therapeutics (CYTO) has released an update. Altamira Therapeutics has reported a net loss from continuing operations of $4,339,832 for the...

Altamira Therapeutics Reports Narrowed Losses

Altamira Therapeutics Ltd. (CYTO) Q2 2024 Earnings Call Transcript

Altamira Therapeutics receives Nasdaq non-compliance letter

Altamira Therapeutics (CYTO) has released an update. Altamira Therapeutics Ltd. has been notified by Nasdaq of non-compliance with the minimum bid ...

Altamira Therapeutics Faces Nasdaq Delisting

AISP

ALBT

ARAY

CYTO

DFLI

FFIE

HPCO

LITE

ONCO

ORGN

SIRI

SPIR

SPRC

TITN

TSBX

ULTA

VSME

Press Releases

Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark

Analyst Ratings

Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO)

Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11

Health Care

Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia

Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering

Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering

Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results

Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray

Comments

Altamira Therapeutics

Vendite allo scoperto

Altamira Therapeutics (NASDAQ:CYTO) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO